Weight Loss Drugs vs. Fractures

Ozempic may actually protect your bones — even as it strips away the weight that was holding them up.

Quick Take

A real-world study of over 92,000 patients found semaglutide users had 26% fewer bone fractures than patients who had sleeve gastrectomy weight-loss surgery over three years.
A separate analysis found semaglutide linked to 15% fewer fractures in people with type 2 diabetes compared to other weight-loss drugs.
Bone density scans still show modest bone loss with semaglutide, creating a confusing split between what scans show and what actually breaks.
Experts say the evidence is promising but not settled — older patients and those with very high body mass index may face a different risk picture entirely.

The Fracture Finding That Surprised Researchers

Losing a lot of weight is supposed to be hard on your bones. Less body weight means less mechanical pressure on the skeleton, which can trigger bone loss. That is why bariatric surgery patients are monitored closely for fractures. So when researchers compared semaglutide users to sleeve gastrectomy patients and found fewer fractures in the drug group, it turned heads. The semaglutide group had 86 fractures, or about 3%, versus 128 fractures, or about 4.4%, in the surgery group over three years. ^[4]

The study used electronic health records from over 161 million patients seen at U.S. hospitals and clinics. Researchers matched patients by how much weight they lost, so the difference in fracture rates was not simply because surgery patients lost more weight. After that matching, semaglutide still came out ahead. The authors called it a 26% reduction in fracture risk. ^[8] That is a meaningful number — but the study was observational, meaning it shows a pattern, not a proven cause.

A Second Study Points the Same Direction

A study presented at the Endocrine Society’s 2026 annual meeting added more weight to the finding. In people with type 2 diabetes, semaglutide was tied to 15% fewer fractures compared to other anti-obesity medications — and this group also lost more weight. ^[10] That is the counterintuitive part. More weight loss usually means more bone stress, yet the semaglutide group still came out with fewer broken bones. Researchers stopped short of claiming the drug directly protects bone, but they said prospective studies should follow up on the signal.

What Animal Studies Suggest About Why This Could Happen

Glucagon-like peptide-1 receptor agonists — the drug class that includes semaglutide — appear to interact with bone cells in animal models. Early research shows these drugs may increase osteoblast activity, which builds bone, while reducing osteoclast activity, which breaks it down. ^[2] If that mechanism holds in humans, it could explain why fracture rates drop even when bone density measurements dip slightly. Bone quality and bone density are not the same thing. A bone can look thinner on a scan and still resist fracture better if its internal structure is healthier.

The Bone Density Problem That Complicates the Story

Here is where the story gets messy. A randomized, placebo-controlled trial in adults with elevated fracture risk found that semaglutide did not improve bone formation markers and actually lowered bone mineral density at the spine and hip. ^[1] A separate study found that weight loss from semaglutide and tirzepatide was directly linked to bone loss at the hip, especially in patients without diabetes. ^[3] So the scans look worse, but actual fractures appear to happen less often. That gap between surrogate measures and real outcomes is one of the most common and frustrating puzzles in medicine.

A large real-world study suggests semaglutide (Ozempic, Wegovy, Rybelsus) may offer an unexpected bonus for people with type 2 diabetes: stronger protection against bone fractures while delivering greater weight loss. Researchers analyzing health records fhttps://t.co/umCNFwEAZi

— Michael W. Deem (@Michael_W_Deem) June 16, 2026

Food and Drug Administration labeling for semaglutide already flags a possible fracture risk in older adults and women. In one large cardiovascular outcomes study, women on semaglutide had hip and pelvic fractures at a rate of 1% versus 0.2% for placebo. ^[6] For patients over 75, fracture rates were 2.4% on semaglutide versus 0.6% on placebo. Those numbers deserve serious attention. The favorable fracture data in the observational studies skews younger, with an average patient age of 45. Age matters enormously here.

What This Means If You or Someone You Know Takes Ozempic

The honest answer right now is that semaglutide’s effect on bone is genuinely unsettled. For middle-aged adults using the drug to lose weight, the fracture data looks more reassuring than alarming — especially compared to surgery. For older adults, particularly women over 65 with high body mass index, the picture is murkier and the risk may run the other way. Resistance training, adequate protein, calcium, and vitamin D remain the best-proven tools for protecting bone during any significant weight loss, drug-assisted or not. No study has untangled how much of the fracture difference comes from the drug itself versus better nutrition, more exercise, or simply avoiding the trauma of surgery.